Biomarin Pharmaceut (BMRN) 80.09 $BMRN
BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
GlobeNewswire - Mon Jun 20, 3:35PM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentation will report interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration.
BMRN: 80.08 (-3.57)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 233.59 (-5.03), BMRN: 80.08 (-3.57), ALXN: 114.06 (-9.51), IBB: 254.02 (-8.08), REGN: 345.89 (-11.25)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 233.59 (-5.03), BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01), ALXN: 114.06 (-9.51), IBB: 254.02 (-8.08), REGN: 345.89 (-11.25)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 80.08 (-3.57), ALXN: 114.06 (-9.51), AEGR: 1.63 (-0.04), ACOR: 25.55 (-0.76)
BioMarin Pharmaceutical Falls 4.20% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 07, 3:13PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $85.23 to a high of $89.30. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $87.17 on volume of 597,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 80.08 (-3.57)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01), PFE: 34.28 (-0.31), BMY: 71.49 (-1.15)
BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 80.08 (-3.57), ANIP: 55.49 (-0.78), SRPT: 17.87 (-0.01), BMY: 71.49 (-1.15)
BioMarin Pharmaceutical Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 3:06PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.35 to a high of $91.25. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $89.85 on volume of 558,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.08 (-3.57)
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa(TM) (drisapersen) in Europe
GlobeNewswire - Tue May 31, 3:05PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa(TM) (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting. Those discussions clearly indicated that the CHMP intended to issue a negative opinion. Kyndrisa is an experimental drug for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
BMRN: 80.08 (-3.57)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 80.08 (-3.57), PFE: 34.28 (-0.31), BMY: 71.49 (-1.15)
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 2.74% Rise
Comtex SmarTrend(R) - Wed May 18, 3:27PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $83.21 to a high of $87.51. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $87.50 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.08 (-3.57)
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 11.89 (-0.36), BMRN: 80.08 (-3.57), PFE: 34.28 (-0.31)
AbSci Appoints Daniel Gold, Ph.D. to Board of Directors
PR Newswire - Mon May 16, 7:00AM CDT
AbSci announced today the appointment of Daniel Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has served in senior management roles at several leading biotechnology companies and currently serves as Vice President of Process Sciences at BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).
BMRN: 80.08 (-3.57)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed May 04, 7:30AM CDT
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas
BMRN: 80.08 (-3.57)
BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
GlobeNewswire - Tue May 03, 7:25AM CDT
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016
BMRN: 80.08 (-3.57)
BioMarin Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:02PM CDT
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
BMRN: 80.08 (-3.57)
Why Sarepta Therapeutics Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 28, 1:36PM CDT
IMAGE SOURCE: TBIT ON PIXABAY. What: Shares of biotech stock Sarepta Therapeutics are surging more than 26% higher as of 1:15 p.m. ET after a bullish article by TheStreet.com's Adam Feurstein suggests that the company's Duchenne muscular...
BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 3.96 (-0.24), BIIB: 233.59 (-5.03), JNJ: 116.44 (-0.94), BMRN: 80.08 (-3.57), SHPG: 168.54 (-11.75), IMGN: 3.23 (-0.09), BXLT: 46.02 (-0.18), KERX: 6.00 (-0.20), NVS: 78.76 (-1.91)
Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:57AM CDT
BioMarin Pharmaceutical (BMRN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
BMRN: 80.08 (-3.57)
BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
GlobeNewswire - Mon Jun 20, 3:35PM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentation will report interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration.
BMRN: 80.08 (-3.57)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 233.59 (-5.03), BMRN: 80.08 (-3.57), ALXN: 114.06 (-9.51), IBB: 254.02 (-8.08), REGN: 345.89 (-11.25)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 233.59 (-5.03), BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01), ALXN: 114.06 (-9.51), IBB: 254.02 (-8.08), REGN: 345.89 (-11.25)
Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 80.08 (-3.57), ALXN: 114.06 (-9.51), AEGR: 1.63 (-0.04), ACOR: 25.55 (-0.76)
BioMarin Pharmaceutical Falls 4.20% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 07, 3:13PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $85.23 to a high of $89.30. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $87.17 on volume of 597,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BMRN: 80.08 (-3.57)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01), PFE: 34.28 (-0.31), BMY: 71.49 (-1.15)
BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 80.08 (-3.57), ANIP: 55.49 (-0.78), SRPT: 17.87 (-0.01), BMY: 71.49 (-1.15)
BioMarin Pharmaceutical Rises 1.39% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue May 31, 3:06PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.35 to a high of $91.25. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $89.85 on volume of 558,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.08 (-3.57)
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa(TM) (drisapersen) in Europe
GlobeNewswire - Tue May 31, 3:05PM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa(TM) (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting. Those discussions clearly indicated that the CHMP intended to issue a negative opinion. Kyndrisa is an experimental drug for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.
BMRN: 80.08 (-3.57)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 80.08 (-3.57), PFE: 34.28 (-0.31), BMY: 71.49 (-1.15)
Look for Shares of BioMarin Pharmaceutical to Potentially Pullback after Yesterday's 2.74% Rise
Comtex SmarTrend(R) - Wed May 18, 3:27PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $83.21 to a high of $87.51. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $87.50 on volume of 599,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 80.08 (-3.57)
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 11.89 (-0.36), BMRN: 80.08 (-3.57), PFE: 34.28 (-0.31)
AbSci Appoints Daniel Gold, Ph.D. to Board of Directors
PR Newswire - Mon May 16, 7:00AM CDT
AbSci announced today the appointment of Daniel Gold, Ph.D. to AbSci's Board of Directors. Dr. Gold has served in senior management roles at several leading biotechnology companies and currently serves as Vice President of Process Sciences at BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN).
BMRN: 80.08 (-3.57)
BioMarin to Attend Upcoming Investor Conferences
GlobeNewswire - Wed May 04, 7:30AM CDT
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas
BMRN: 80.08 (-3.57)
BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, Experimental Treatment for a Form of Batten Disease
GlobeNewswire - Tue May 03, 7:25AM CDT
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016
BMRN: 80.08 (-3.57)
BioMarin Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 3:02PM CDT
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
BMRN: 80.08 (-3.57)
Why Sarepta Therapeutics Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Thu Apr 28, 1:36PM CDT
IMAGE SOURCE: TBIT ON PIXABAY. What: Shares of biotech stock Sarepta Therapeutics are surging more than 26% higher as of 1:15 p.m. ET after a bullish article by TheStreet.com's Adam Feurstein suggests that the company's Duchenne muscular...
BMRN: 80.08 (-3.57), SRPT: 17.87 (-0.01)
Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 3.96 (-0.24), BIIB: 233.59 (-5.03), JNJ: 116.44 (-0.94), BMRN: 80.08 (-3.57), SHPG: 168.54 (-11.75), IMGN: 3.23 (-0.09), BXLT: 46.02 (-0.18), KERX: 6.00 (-0.20), NVS: 78.76 (-1.91)
Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 7:57AM CDT
BioMarin Pharmaceutical (BMRN) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory
BMRN: 80.08 (-3.57)
